Gene therapy trials target diabetic neuropathy.
Investigators are testing a variety of ways to deliver potentially therapeutic genes through direct injection of vascular endothelial growth factor (VEGF) DNA into muscles or via vectors created from adeno-associated virus or herpes simplex virus (HSV).
Although these small phase I or II trials are focused on safety outcomes, they have produced tantalizing suggestions of improvements in painful diabetic neuropathy and increased muscle size in some patients who have muscular dystrophy.
The muscular dystrophy studies also have identified surprising immune barriers to gene transfer in human patients that have not been seen in animal studies.
The researchers described preliminary results and new insights from these early and ongoing trials in a series of talks at the meeting.
Dr. Allan H. Ropper, professor of neurology at Harvard Medical School, Boston, led a randomized, blinded trial of gene therapy in 50 patients with diabetic neuropathy who received intramuscular injections of a plasmid containing VEGF or injections of saline serving as placebo. Three sets of injections were given at eight sites next to the sciatic, peroneal, and tibial nerves of one leg.
In the 39 patients who received the VEGF plasmid, Dr. Ropper and his associates detected modest improvement in the trial's primary outcomes - changes in symptom scores at 6 months and a pre-specified overall clinical and electrophysiological improvement score - when compared with 11 patients who received placebo. These comparisons were adjusted for any changes in the untreated leg.
Overall improvement was seen in 12 of the 39 patients who got plasmid VEGF and 2 of the 11 who got placebo (Ann. Neurol. 2009;65:386-93). Dr. Ropper called the improvements "small but genuine."
The treatment was associated with a higher rate of serious adverse events, which did not reach statistical significance. Overall, the therapy warrants further investigation, he said.
Other promising data have come from animal studies of VEGF gene transfer before chemotherapy with thalidomide and cisplatin to prevent neuropathies associated with those drugs, Dr. Ropper noted. Human trials to prevent neuropathy of chemotherapy are being considered.
Dr. David J. Fink, who chaired the meeting session, described nonreplicating HSV vectors he and his colleagues are developing. Cutaneous injection of the vectors may deliver genes to specific targets in order to interrupt nociceptive neurotransmission and better control chronic pain.
In an ongoing phase I clinical trial of patients with intractable pain from end-stage cancer, Dr. Fink and his colleagues are testing an HSV vector that carries the gene for preproenkephalin. In animal studies, the HSV vector containing the preproenkephalin gene produced enkephalin, which provided a continuous analgesic effect.
In the human trial, patients receive 10 injections of the vector in 100-mcL doses in the dermatome that corresponds to the distribution of the pain. No serious adverse events have occurred so far, said Dr. Fink, chair of neurology at the University of Michigan, Ann Arbor. Diamyd Medical, which makes the vector, has agreed to start a randomized phase II trial in the fall of 2010.
A separate randomized, placebo-controlled, phase I/II study also should start in late 2010 to treat 60 patients with painful diabetic neuropathy using a different HSV vector that Dr. Fink and his associates have developed.
For patients with Duchenne muscular dystrophy, Dr. Jerry R. Mendell reported that the concept of using a virus as a vehicle to replace a defective gene might run into unanticipated barriers presented by the human immune system. He and his associates have focused on the relatively nonpathogenic adeno-associated virus.
Duchenne muscular dystrophy is caused by mutations in the very large dystrophin gene, which is too large to transfer when incorporated into the tiny adeno-associated virus. To get around this problem, the researchers deleted portions of the gene to create a "mini-dystrophin" that could be transferred using the virus.
When investigators transferred the adeno-associated virus with mini-dystrophin to the biceps of six patients with Duchenne muscular dystrophy, it provoked an unexpected immune response. Muscle fibers that expressed the mini-dystrophin gene also developed new epitopes that were immunogenic, making it difficult for the transferred gene to escape T-cell immunity, said Dr. Mendell, director of the Center for Gene Therapy at Nationwide Children's Hospital and professor of pediatrics and neurology at Ohio State University, both in Columbus.
In a separate study, he and his associates transferred the large limb-girdle muscular dystrophy type 2D gene via the adeno-associated virus (Ann. Neurol. 2009;66:290-7). New data on 6-month follow-up in six patients who received the gene therapy injections in the extensor digitorum brevis muscle showed persistent gene expression and muscle effects in five patients.
Diamyd Medical funded Dr. Fink's trial and provided the vectors for it. Dr. Fink said he has no financial relationship with Diamyd, but he is the inventor on patents that have been licensed by Diamyd from his institution and two others. Dr. Ropper and Dr. Mendell said they have no pertinent conflicts of interest.
BY SHERRY BOSCHERT
FROM THE ANNUAL MEETING OF THE AMERICAN NEUROLOGICAL ASSOCIATION
|Printer friendly Cite/link Email Feedback|
|Publication:||Internal Medicine News|
|Date:||Oct 15, 2010|
|Previous Article:||Daily imiquimod topped placebo for genital wart treatment.|
|Next Article:||Ginseng may improve working memory in young adults.|